Clinical trial
Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung…
NCT00004883 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004883 |
|---|---|
| Title | Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2 |
| Official title | A Phase II Trial of Trastuzumab (Herceptin) for Advanced Stage (IIIB, IV), HER2 Overexpressing, Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Biological, Other |
| Interventions | trastuzumab, laboratory biomarker analysis |
| Enrollment | 84 |
| Start date | Feb 1, 2000 |
| Primary completion | Aug 1, 2005 |
| First posted | Sep 30, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: